RxDoctor Payments Data

Bikash Bhattarai

Pulmonary Disease · Chambersburg, PANPI 1164839965

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 56 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$617
  • Intuitive Surgical$160
  • Grifols USA, LLC$127
  • Fisher & Paykel Healthcare Inc$93
  • AstraZeneca$74
  • Insmed, Inc.$73
  • plus $332 from 7 others

What the payments were for

  • Food & beverage$1,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,477 in reported general payments places this provider in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,246
Medicare patients
520
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter283$213,503
OfevNintedanib Esylate11$146,506
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr71$45,634
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$17,504
Breo ElliptaFluticasone/Vilanterol24$14,489
Combivent RespimatIpratropium/Albuterol Sulfate30$14,267
Spiriva RespimatTiotropium Bromide27$13,901
Incruse ElliptaUmeclidinium Bromide18$9,539
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,517
Albuterol Sulfate HfaAlbuterol Sulfate221$6,356
Advair HfaFluticasone Propion/Salmeterol12$4,539
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,212
BreynaBudesonide/Formoterol Fumarate11$2,313
Ventolin HfaAlbuterol Sulfate36$1,950
Montelukast Sodium90$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$18$283,165396 claims
Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat$617$184,19187 claims
AstraZenecaBreztri Aerosphere$74$17,50426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →